Fig. 1 · Structure

Documents & Downloads

SU14813 maleate

Cat. No. A11556 CAS 849643-15-8

multi-targeted receptor tyrosine kinases inhibitor

SU14813 maleate is a multi-targeted receptor tyrosine kinases inhibitor with IC50s of 50, 2, 4, 15 nM for VEGFR2, VEGFR1, PDGFRβ and KIT.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
VEGFR1 IC50 2 nM
VEGFR2 IC50 50 nM
PDGFRβ IC50 4 nM
KIT IC50 15 nM

SU14813 maleate Research Summary

This section summarizes 2 in vitro studies and 1 in vivo study of SU14813 maleate from 2 published references. In vitro models include RD cells; SK‐MEL‐28 cells.

SU14813 maleate In Vitro Studies

In RD cells, SU14813 had a 50% cytotoxicity concentration (CC50) of 26.35 ± 6.09 μM. In SK‐MEL‐28 cells treated with 10 µM SU14813 for 48 h, CETSA showed that SU14813 binding significantly reduced WDR12 thermal stability, decreasing the Tm from 63.63°C in the control group to 57.38°C in the SU14813‐treated group. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

50% cytotoxicity concentration (CC50) in RD cells

Cell-based study · RD cells [1]

Model: RD cells. Result: 26.35 ± 6.09 μM.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
50% cytotoxicity concentration (CC50)CC50 26.35 ± 6.09 μM[1]

Literature-Reported Treatment Conditions

Reported limits
Not stated in the sentences used: dose, route, schedule, vehicle, control.
Methods and source locations

Compound reported in the paper: SU14813

The paper names SU14813 without stating the salt or form; not verified as the maleate form supplied as A11556. No dose conversion or lot validation.

RESULTS > Inhibition of EV-A71 infection in vitro by VEGFR inhibitors (S73); TABLE 1 (T1.h1, T1.r4)

50% cytotoxicity concentration (CC50): 50% cytotoxicity concentration (CC50) — RESULTS > Inhibition of EV-A71 infection in vitro by VEGFR inhibitors (S73); TABLE 1 (T1.h1, T1.r4)

Protein Thermal Stability in Melanoma Cells

Cell-based study · SK‐MEL‐28 cells [2]

SK‐MEL‐28 cells were treated with DMSO or 10 µM SU14813 for 48 h and assessed by CETSA. SU14813 binding significantly reduced WDR12 thermal stability, decreasing the Tm from 63.63°C in the control group to 57.38°C in the SU14813‐treated group.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
CETSA analysis of SU14813 on the thermal stability of target protein WDR12Tm 63.63°C in the control group to 57.38°C in the SU14813‐treated group[2]

Literature-Reported Treatment Conditions

Treatment concentration
10 µM
Exposure duration
for 48 h
Method
treated with DMSO or SU14813
Vehicle
DMSO
Methods and source locations

Compound reported in the paper: SU14813

The paper names SU14813 without stating the salt or form; not verified as the maleate form supplied as A11556. No dose conversion or lot validation.

Results > The Small‐Molecule Compound SU14813 Targeting WDR12 Downregulates CD276 and Potentiates CD8+ T‐Cell Antitumor Function (S89); FIGURE 5 legend (S278, S279)

CETSA analysis of SU14813 on the thermal stability of target protein WDR12: CETSA analysis of SU14813 on the thermal stability of target protein WDR12; comparator: DMSO — Results > The Small‐Molecule Compound SU14813 Targeting WDR12 Downregulates CD276 and Potentiates CD8+ T‐Cell Antitumor Function (S89); FIGURE 5 legend (S278)

SU14813 maleate In Vivo Studies

Female C57BL/6 mice subcutaneously inoculated with wild‐type B16F10 cells received daily oral SU14813. Tumor growth curves showed that SU14813 treatment significantly inhibited tumor growth compared with the vehicle group. [2]

Tumor Growth Inhibition in a Mouse Model

Animal study · wild‐type B16F10 cells were subcutaneously inoculated into female C57BL/6 mice; n = 5 [2]

Female C57BL/6 mice subcutaneously inoculated with wild‐type B16F10 cells received SU14813 orally each day. Compared with the vehicle group, SU14813 treatment significantly inhibited tumor growth.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
tumor growth curveReported result compared with the vehicle group, SU14813 treatment significantly inhibited tumor growth[2]

Conditions shared by the study groups

Route
oral administration
Treatment course
daily
Vehicle
vehicle
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
SU14813 10‐mg/kg SU14813, 20‐mg/kg SU14813, or 40‐mg/kg SU14813vehicle groupcompared with the vehicle group, SU14813 treatment significantly inhibited tumor growth[2]
SU14813 10‐mg/kg SU14813, 20‐mg/kg SU14813, or 40‐mg/kg SU14813
Model: wild‐type B16F10 cells were subcutaneously inoculated into female C57BL/6 mice; n = 5
Reported limits: Dose removed by unit check.
Methods and source locations

Compound reported in the paper: SU14813

The paper names SU14813 without stating the salt or form; not verified as the maleate form supplied as A11556. No dose conversion or lot validation.

Results > The Small‐Molecule Compound SU14813 Targeting WDR12 Downregulates CD276 and Potentiates CD8+ T‐Cell Antitumor Function (S100); Materials and Methods > Animal Experiments (S168, S169); FIGURE 5 legend (S285)

tumor growth curve: tumor growth curve; comparator: vehicle group — Results > The Small‐Molecule Compound SU14813 Targeting WDR12 Downregulates CD276 and Potentiates CD8+ T‐Cell Antitumor Function (S100); FIGURE 5 legend (S285)

SU14813 10‐mg/kg SU14813, 20‐mg/kg SU14813, or 40‐mg/kg SU14813 · Results > The Small‐Molecule Compound SU14813 Targeting WDR12 Downregulates CD276 and Potentiates CD8+ T‐Cell Antitumor Function (S100); Materials and Methods > Animal Experiments (S169)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 849643-15-8
Applications multi-targeted receptor tyrosine kinases inhibitor
Formula C27H31FN4O8
Molecular Weight 558.56
SMILES
O=C(NC[C@@H](CN1CCOCC1)O)C2=C(NC(/C=C3C(NC4=C\3C=C(C=C4)F)=O)=C2C)C.O=C(/C=C\C(O)=O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

SU14813 maleate Research References

  1. [1] Zhao X, Qiao R, Hao M, et al. Vascular endothelial growth factor receptor 2 as a potential host target for the inhibition of enterovirus replication. J Virol (2024). PMID: 39287389 DOI: 10.1128/jvi.01129-24 Source material
  2. [2] Pan J, Chang R, Zhang M, et al. Targeting WDR12 Unleashes T-Cell-Mediated Antitumor Activity in Melanoma by Destabilizing CD276. Adv Sci (Weinh) (2026). PMID: 42363820 DOI: 10.1002/advs.76255 Source material

Added to your cart

View Cart Checkout
Loading...